アミロイドーシス治療市場：タイプ別、エンドユーザー別-2025-2030年の世界予測

アミロイドーシス治療市場は、2023年に52億3,000万米ドルと評価され、2024年には57億米ドルに達すると予測され、CAGR 7.57％で成長し、2030年には87億3,000万米ドルに達すると予測されています。

アミロイドーシス治療は、臓器や組織におけるアミロイドタンパク質の異常蓄積を特徴とする希少疾患であるアミロイドーシスを管理するために採用される戦略と治療法を指します。アミロイドーシス治療の範囲には、薬物療法、幹細胞移植、支持療法などが含まれ、それぞれが症状の管理、病気の進行の抑制、生活の質の向上を目的としています。これらの治療の必要性は、ALアミロイドーシスやATTRアミロイドーシスのように、心臓、腎臓、肝臓、神経系などの臓器に影響を及ぼす可能性のある多様なアミロイドーシスを対象とする能力によって強調されます。治療の用途は医療施設から在宅医療まで幅広く、最終用途は病院、専門クリニック、研究機関に及ぶ。市場成長は、製薬研究の進歩、希少疾患に対する意識の高まり、診断手法の改善によって大きく左右されます。特に、RNA干渉に基づく治療法などの最近の革新的な治療法の普及に伴い、新規治療法や個別化医療アプローチの開発に主な潜在機会が存在します。しかし、治療費の高騰、疾病管理の複雑さ、疾患の希少性といった課題もあり、市場の拡大には限界があります。新たな技術革新の機会としては、疾患の病因をより深く理解するための遺伝子研究の進展や、早期診断と治療モニタリングのためのより効果的なバイオマーカーの開発などが挙げられます。さらに、市場の性質はニッチでありながら、継続的な研究と投資によって大きな成果を上げており、費用対効果の高い革新的なソリューションを提供できる新規参入者に道を開いています。技術革新の重点分野には、ドラッグデリバリーシステムの強化、併用療法の探求、治療成績の予測分析のための人工知能の活用などがあります。最適な事業成長のためには、医薬品承認を迅速化するための規制当局との連携や、研究開発のための戦略的パートナーシップの形成が推奨されるほか、認知度向上や早期診断イニシアチブを強化するためのヘルスケアプロバイダーとの協力関係の醸成も重要です。

市場力学：急速に進化するアミロイドーシス治療市場の主要市場インサイトを公開

アミロイドーシス治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業組織は十分な情報に基づいた投資決定、戦略的決定の精緻化、新たなビジネスチャンスの獲得を行うことができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 増加する巨大人口におけるアミロイドーシスの顕著な有病率
  • 早期診断とアミロイドーシス治療に対する意識の高まり
  • 新規アミロイドーシス治療薬開発のための活発な研究活動
• 市場抑制要因
  • アミロイドーシス治療薬の高コストと償還政策に関する問題
• 市場機会
  • アミロイドーシス治療のための新しい治療法の出現
  • 近代化されたヘルスケア・インフラ整備のための投資の増加
• 市場の課題
  • アミロイドーシス治療に伴う複雑性とリスク

ポーターの5つの力：アミロイドーシス治療市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：アミロイドーシス治療市場における外部からの影響の把握

外部マクロ環境要因は、アミロイドーシス治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析アミロイドーシス治療市場における競合情勢の把握

アミロイドーシス治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスアミロイドーシス治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、アミロイドーシス治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨アミロイドーシス治療市場における成功への道筋を描く

アミロイドーシス治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 人口増加に伴うアミロイドーシスの有病率の上昇
    • アミロイドーシスの早期診断と治療に関する意識の高まり
    • アミロイドーシスの新規治療薬開発に向けた活発な調査活動
  • 抑制要因
    • アミロイドーシス治療の高額な費用と償還政策に関する問題
  • 機会
    • アミロイドーシス治療の新た治療選択肢の出現
    • 近代化されたヘルスケアインフラの開発への投資増加
  • 課題
    • アミロイドーシス治療に伴う複雑さとリスク
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 アミロイドーシス治療市場：タイプ別

• 薬物治療
  • 化学療法
  • 標的療法
    • 抗血管新生療法
    • モノクローナル抗体
    • プロテアソーム阻害剤
• 手術
  • 骨髄移植/幹細胞移植
  • 臓器移植

第7章 アミロイドーシス治療市場：エンドユーザー別

• 病院
• 専門センター

第8章 南北アメリカのアミロイドーシス治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域のアミロイドーシス治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカのアミロイドーシス治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbvie, Inc.
• Acrotech Biopharma, Inc
• Alexion Pharmaceuticals
• Alnylam Pharmaceuticals Inc.
• Arcturus Therapeutics, Inc.
• Astellas Pharma, Inc.
• AstraZeneca PLC
• Attralus, Inc.
• BridgeBio Pharma, Inc.
• Bristol-Myers Squibb Company
• Corino Therapeutics, Inc.
• GlaxoSmithKline PLC
• Ionis Pharmaceuticals, Inc.
• Johnson & Johnson Services Inc
• Merck & Co., Inc.
• Neurimmune AG
• Oncopeptides AB
• Pfizer Inc.
• Proclara Biosciences Inc.
• Prothena Corporation PLC
• Regeneron Pharmaceuticals Inc.
• SOM INNOVATION BIOTECH, SA,
• Sorrento Therapeutics, Inc.
• Spectrum Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited

LIST OF FIGURES

• FIGURE 1. AMYLOIDOSIS TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. AMYLOIDOSIS TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. AMYLOIDOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. AMYLOIDOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. AMYLOIDOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. AMYLOIDOSIS TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ANTI-ANGIOGENESIS THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANTATION/STEM CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORGAN TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 39. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 41. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 42. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 43. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 61. AUSTRALIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. AUSTRALIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 63. AUSTRALIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 64. AUSTRALIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 66. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 68. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 69. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 70. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 71. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 73. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 74. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 75. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 76. INDONESIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. INDONESIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 78. INDONESIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 79. INDONESIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 81. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 83. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 84. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 86. MALAYSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. MALAYSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 88. MALAYSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 89. MALAYSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 91. PHILIPPINES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. PHILIPPINES AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 93. PHILIPPINES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 94. PHILIPPINES AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 96. SINGAPORE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. SINGAPORE AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 98. SINGAPORE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 99. SINGAPORE AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 101. SOUTH KOREA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. SOUTH KOREA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 103. SOUTH KOREA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 104. SOUTH KOREA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 106. TAIWAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. TAIWAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 108. TAIWAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 109. TAIWAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 111. THAILAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. THAILAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 113. THAILAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 114. THAILAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 116. VIETNAM AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. VIETNAM AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 118. VIETNAM AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 119. VIETNAM AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 121. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 123. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 124. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 127. DENMARK AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. DENMARK AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 129. DENMARK AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 130. DENMARK AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 132. EGYPT AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. EGYPT AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 134. EGYPT AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 135. EGYPT AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 137. FINLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. FINLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 139. FINLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 140. FINLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 142. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 144. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 145. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 147. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 148. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 149. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 150. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 152. ISRAEL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 153. ISRAEL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 154. ISRAEL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 155. ISRAEL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 157. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 158. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 159. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 160. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 161. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 162. NETHERLANDS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 163. NETHERLANDS AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 164. NETHERLANDS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 165. NETHERLANDS AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 167. NIGERIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 168. NIGERIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 169. NIGERIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 170. NIGERIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 172. NORWAY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 173. NORWAY AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 174. NORWAY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 175. NORWAY AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 177. POLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 178. POLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 179. POLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 180. POLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 181. POLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 182. QATAR AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 183. QATAR AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 184. QATAR AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 185. QATAR AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 186. QATAR AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 187. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 188. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 189. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 190. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 192. SAUDI ARABIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 193. SAUDI ARABIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 194. SAUDI ARABIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 195. SAUDI ARABIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 197. SOUTH AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 198. SOUTH AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 199. SOUTH AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 202. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 203. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 204. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 205. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 207. SWEDEN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 208. SWEDEN AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 209. SWEDEN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 210. SWEDEN AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 212. SWITZERLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 213. SWITZERLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 214. SWITZERLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 215. SWITZERLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 217. TURKEY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 218. TURKEY AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 219. TURKEY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 220. TURKEY AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 222. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 223. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 224. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 225. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 227. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 228. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 229. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 230. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 232. AMYLOIDOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 233. AMYLOIDOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Amyloidosis Treatment Market was valued at USD 5.23 billion in 2023, expected to reach USD 5.70 billion in 2024, and is projected to grow at a CAGR of 7.57%, to USD 8.73 billion by 2030.

Amyloidosis treatment refers to the strategies and therapies employed to manage amyloidosis, a rare disease characterized by abnormal accumulation of amyloid proteins in organs and tissues. The scope of amyloidosis treatment involves modalities such as medication, stem cell transplantation, and supportive care, each tailored to manage symptoms, slow disease progression, and improve quality of life. The necessity of these treatments is underscored by their ability to target diverse forms of amyloidosis, addressing conditions like AL amyloidosis and ATTR amyloidosis, which can affect organs including the heart, kidneys, liver, and nervous system. Applications of treatment extend from healthcare facilities to home care, with end-use spanning hospitals, specialty clinics, and research institutes. Market growth is influenced significantly by advances in pharmaceutical research, increasing awareness about rare diseases, and improved diagnostic methodologies. Key potential opportunities reside in the development of novel therapeutics and personalized medicine approaches, particularly as recent innovations such as RNA interference-based therapies gain traction. However, the market faces challenges such as high costs of treatment, the complexity of disease management, and the rarity of the condition, which limits broad market expansion. Emerging opportunities for innovation include advancements in genetic research to better understand the disease pathogenesis and the development of more effective biomarkers for early diagnosis and treatment monitoring. Further, the market's nature remains niche yet marked by significant ongoing research and investment, paving the way for new entrants who can bring cost-effective, innovative solutions. Focus areas for innovation include enhancing drug delivery systems, exploring combination therapies, and harnessing artificial intelligence for predictive analytics in treatment outcomes. For optimal business growth, aligning with regulatory pathways to expedite drug approvals and forming strategic partnerships for research and development are recommended, alongside fostering collaborations with healthcare providers to enhance awareness and early diagnosis initiatives.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Amyloidosis Treatment Market

The Amyloidosis Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Significant prevalence of amyloidosis among rising gigantic population
  • Growing awareness about early diagnosis and amyloidosis treatments
  • Robust research activities to develop novel amyloidosis drugs
• Market Restraints
  • Issues related to high cost and reimbursement policies of amyloidosis treatments
• Market Opportunities
  • Emergence of new treatment options for treating amyloidosis
  • Rising investments to develop modernized healthcare infrastructure
• Market Challenges
  • Complexities and risk associated with amyloidosis treatments

Porter's Five Forces: A Strategic Tool for Navigating the Amyloidosis Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Amyloidosis Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Amyloidosis Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Amyloidosis Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Amyloidosis Treatment Market

A detailed market share analysis in the Amyloidosis Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Amyloidosis Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Amyloidosis Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Amyloidosis Treatment Market

A strategic analysis of the Amyloidosis Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Amyloidosis Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbvie, Inc., Acrotech Biopharma, Inc, Alexion Pharmaceuticals, Alnylam Pharmaceuticals Inc., Arcturus Therapeutics, Inc., Astellas Pharma, Inc., AstraZeneca PLC, Attralus, Inc., BridgeBio Pharma, Inc., Bristol-Myers Squibb Company, Corino Therapeutics, Inc., GlaxoSmithKline PLC, Ionis Pharmaceuticals, Inc., Johnson & Johnson Services Inc, Merck & Co., Inc., Neurimmune AG, Oncopeptides AB, Pfizer Inc., Proclara Biosciences Inc., Prothena Corporation PLC, Regeneron Pharmaceuticals Inc., SOM INNOVATION BIOTECH, SA,, Sorrento Therapeutics, Inc., Spectrum Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Amyloidosis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Medication and Surgery. The Medication is further studied across Chemotherapy and Targeted therapy. The Targeted therapy is further studied across Anti-Angiogenesis Therapy, Monoclonal Antibodies, and Proteasome Inhibitors. The Surgery is further studied across Bone Marrow Transplantation/Stem Cell Transplantation and Organ Transplantation.
• Based on End-Users, market is studied across Hospitals and Specialty Centers.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Significant prevalence of amyloidosis among rising gigantic population
    • 5.1.1.2. Growing awareness about early diagnosis and amyloidosis treatments
    • 5.1.1.3. Robust research activities to develop novel amyloidosis drugs
  • 5.1.2. Restraints
    • 5.1.2.1. Issues related to high cost and reimbursement policies of amyloidosis treatments
  • 5.1.3. Opportunities
    • 5.1.3.1. Emergence of new treatment options for treating amyloidosis
    • 5.1.3.2. Rising investments to develop modernized healthcare infrastructure
  • 5.1.4. Challenges
    • 5.1.4.1. Complexities and risk associated with amyloidosis treatments
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Amyloidosis Treatment Market, by Type

• 6.1. Introduction
• 6.2. Medication
  • 6.2.1. Chemotherapy
  • 6.2.2. Targeted therapy
    • 6.2.2.1. Anti-Angiogenesis Therapy
    • 6.2.2.2. Monoclonal Antibodies
    • 6.2.2.3. Proteasome Inhibitors
• 6.3. Surgery
  • 6.3.1. Bone Marrow Transplantation/Stem Cell Transplantation
  • 6.3.2. Organ Transplantation

7. Amyloidosis Treatment Market, by End-Users

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Specialty Centers

8. Americas Amyloidosis Treatment Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Amyloidosis Treatment Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Amyloidosis Treatment Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbvie, Inc.
• 2. Acrotech Biopharma, Inc
• 3. Alexion Pharmaceuticals
• 4. Alnylam Pharmaceuticals Inc.
• 5. Arcturus Therapeutics, Inc.
• 6. Astellas Pharma, Inc.
• 7. AstraZeneca PLC
• 8. Attralus, Inc.
• 9. BridgeBio Pharma, Inc.
• 10. Bristol-Myers Squibb Company
• 11. Corino Therapeutics, Inc.
• 12. GlaxoSmithKline PLC
• 13. Ionis Pharmaceuticals, Inc.
• 14. Johnson & Johnson Services Inc
• 15. Merck & Co., Inc.
• 16. Neurimmune AG
• 17. Oncopeptides AB
• 18. Pfizer Inc.
• 19. Proclara Biosciences Inc.
• 20. Prothena Corporation PLC
• 21. Regeneron Pharmaceuticals Inc.
• 22. SOM INNOVATION BIOTECH, SA,
• 23. Sorrento Therapeutics, Inc.
• 24. Spectrum Pharmaceuticals, Inc.
• 25. Takeda Pharmaceutical Company Limited